These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35301096)

  • 1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Fleming GF; Pagani O; Regan MM; Walley BA; Francis PA
    Ann Oncol; 2022 Jun; 33(6):658. PubMed ID: 35301096
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
    Toi M; Boyle F; Im YH; Reinisch M; Molthrop D; Jiang Z; Wei R; Sapunar F; Grimes BR; Nabinger SC; Johnston SRD
    Oncologist; 2023 Jan; 28(1):e77-e81. PubMed ID: 36342342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'.
    Harbeck N; Rastogi P; Shahir A; Johnston S; O'Shaughnessy J
    Ann Oncol; 2022 Feb; 33(2):227-228. PubMed ID: 34756989
    [No Abstract]   [Full Text] [Related]  

  • 5. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study.
    Johnston SRD; Rugo HS; Tolaney SM; Munoz Fernandez M; Wei R; Martin M
    Future Oncol; 2024; 20(28):2037-2048. PubMed ID: 39023253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer.
    Meirson T; Goldstein DA; Gyawali B; Tannock IF
    Lancet Oncol; 2023 Jun; 24(6):589-593. PubMed ID: 37146621
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    Royce M; Osgood C; Mulkey F; Bloomquist E; Pierce WF; Roy A; Kalavar S; Ghosh S; Philip R; Rizvi F; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    J Clin Oncol; 2022 Apr; 40(11):1155-1162. PubMed ID: 35084948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
    Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
    J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
    Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey EJ
    Farm Hosp; 2024; 48(2):T75-T78. PubMed ID: 38114413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey Emilio J
    Farm Hosp; 2024; 48(2):75-78. PubMed ID: 37735004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy.
    Sun R; Wei LJ
    JAMA Oncol; 2022 Nov; 8(11):1701. PubMed ID: 36173642
    [No Abstract]   [Full Text] [Related]  

  • 14. Abemaciclib Shows Promise for Early Breast Cancer.
    Cancer Discov; 2017 Feb; 7(2):119-120. PubMed ID: 27986713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
    Johnston SRD; Tolaney SM; O'Shaughnessy J; Rastogi P; Harbeck N; Martin M
    Lancet Oncol; 2023 Jun; 24(6):e238. PubMed ID: 37146620
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy-Reply.
    Wei RJ; Martin M; Johnston SRD
    JAMA Oncol; 2022 Nov; 8(11):1702. PubMed ID: 36173623
    [No Abstract]   [Full Text] [Related]  

  • 17. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    Giordano SH; Freedman RA; Somerfield MR;
    J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.